UBS Group AG - LIXTE BIOTECHNOLOGY HLDGS IN ownership

LIXTE BIOTECHNOLOGY HLDGS IN's ticker is LIXT and the CUSIP is 539319202. A total of 16 filers reported holding LIXTE BIOTECHNOLOGY HLDGS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS Group AG ownership history of LIXTE BIOTECHNOLOGY HLDGS IN
ValueSharesWeighting
Q1 2023$8,867
+83.5%
10,722
+13.2%
0.00%
Q4 2022$4,832
+20.8%
9,475
+32.1%
0.00%
Q3 2022$4,000
+33.3%
7,172
+61.6%
0.00%
Q2 2022$3,000
-66.7%
4,437
-39.4%
0.00%
Q1 2022$9,0000.0%7,319
-2.5%
0.00%
Q4 2021$9,000
+12.5%
7,507
+85.9%
0.00%
Q3 2021$8,000
+33.3%
4,039
+112.0%
0.00%
Q2 2021$6,000
+20.0%
1,905
+13.2%
0.00%
Q4 2020$5,0001,6830.00%
Other shareholders
LIXTE BIOTECHNOLOGY HLDGS IN shareholders Q2 2022
NameSharesValueWeighting ↓
SANTA MONICA PARTNERS LP 166,667$124,0000.09%
SABBY MANAGEMENT, LLC 99,644$74,0000.05%
Almanack Investment Partners, LLC. 248,084$185,0000.02%
Warberg Asset Management LLC 14,500$11,0000.00%
TWO SIGMA INVESTMENTS, LP 16,948$13,0000.00%
WELLS FARGO & COMPANY/MN 49$00.00%
GEODE CAPITAL MANAGEMENT, LLC 25,794$19,0000.00%
STATE STREET CORP 35,956$28,0000.00%
MORGAN STANLEY 71,054$53,0000.00%
Citadel Advisors 30,063$23,0000.00%
View complete list of LIXTE BIOTECHNOLOGY HLDGS IN shareholders